Sanofi's itepekimab COPD mechanism study AERIFY-3 posts results after 2025 completion
A Phase 2a Sanofi trial testing itepekimab's effect on airway inflammation in COPD patients has completed with results now posted.
This week's update covers one completed Sanofi trial with newly posted results.
- This exploratory, two-part, 12-week Phase 2a study evaluated the mechanism of action of itepekimab, an anti-IL-33 monoclonal antibody, and its effect on airway inflammation in former and current smokers with chronic obstructive pulmonary disease, in patients aged 40 to 701. The study, sponsored by Sanofi with Regeneron Pharmaceuticals as collaborator, is registered as NCT05326412 (AERIFY-3). It reached study completion on 2025-07-25, with results first posted 2026-08-31. Enrollment totaled 49 participants, and the primary outcome measured change from baseline in an itepekimab pharmacodynamic score, termed the "Normalized Enrichment Score," derived from gene signatures of former smokers and applied in current smokers with COPD, based on tissue samples from endobronchial biopsies1, bronchial brushings, and nasal brushings.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.